PT  - JOURNAL ARTICLE
AU  - B L Ferraiolo
AU  - J A Moore
AU  - D Crase
AU  - P Gribling
AU  - H Wilking
AU  - R A Baughman
TI  - Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice.
DP  - 1988 Mar 01
TA  - Drug Metabolism and Disposition
PG  - 270--275
VI  - 16
IP  - 2
4099  - http://dmd.aspetjournals.org/content/16/2/270.short
4100  - http://dmd.aspetjournals.org/content/16/2/270.full
SO  - Drug Metab Dispos1988 Mar 01; 16
AB  - The serum pharmacokinetics and the major organs of accumulation of recombinant human tumor necrosis factor-alpha (rHuTNF) were determined in BDF1 mice after intravenous and intramuscular administration. Serum concentrations of immunoreactive protein were determined by enzyme-linked immunosorbent assay, and radioactivity was quantitated by beta and gamma scintigraphy. The serum pharmacokinetics of labeled and unlabeled rHuTNF were identical when administered by the intravenous route. After intravenous doses of 165 to 320 micrograms/kg, the clearance was 2.9-3.6 ml/hr, the initial volume of distribution was 1.4-1.6 ml (70-80 ml/kg), and the half-life was 18.5-19.2 min. Intramuscular administration of 320 micrograms/kg resulted in a peak serum concentration of 112 ng/ml. The time of the peak concentration was 1 hr, and the bioavailability of the intramuscular dose was 12%. The data suggest that the disposition of this protein may be biexponential. If this is the case, the terminal phase would appear to account for less than 1% of the total AUC. Since serum concentrations in the terminal phase are at the sensitivity limit of the assay, a single half-life is reported. 125I-Labeled and metabolically labeled 3H-rHuTNF were used to examine tissue distribution. After intravenous 125I-rHuTNF administration, the rank order of accumulation of the 125I-radiolabel in the major organs (per cent dose per organ over 1440 min) was: liver greater than kidney greater than lung greater than heart greater than spleen. This rank order of accumulation was confirmed by intravenous 3H-rHuTNF administration.(ABSTRACT TRUNCATED AT 250 WORDS)